General
Preferred name
DACOMITINIB HYDRATE
Synonyms
PF-00299804 ()
PF00299804 ()
PF 00299804 ()
PF299804 ()
PF-299804 ()
PF 299804 ()
Dacomitinib (hydrate) ()
DACOMITINIB ()
PF-00299804 (hydrate) ()
PF-299804 (hydrate) ()
Vizimpro ()
Dacomitinib hydrate ()
Dacomitinib monohydrate ()
PF-00299804-03 ()
P&D ID
PD085885
CAS
1042385-75-0
Tags
available
drug
Drug Status
approved
Max Phase
Phase 4
First approval
2018
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Dacomitinib is a second-generation small molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) tyrosine kinase family (ErbB family) with potential anti-tumor activity.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
8
Molecular Weight
487.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
3
cLogP
4.98
TPSA
114.37
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Angiogenesis
JAK/STAT Signaling
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Target
EGFR
Solubility
Soluble in DMSO
Source data
